Mortality in a population-based cohort of patients treated with antiparkinsonian drugs

Acta Neurologica Scandinavica

Volumn 97, Issue 1, 1998, Pages 20-26

  Raschetti, R ^a   Spila Alegiani, S ^a   Vanacore, N ^b   Ancona, C ^c   Meco, G ^b  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c Department of Epidemiology   (Italy)

Author keywords

Antiparkinsonian drugs; Cohort mortality study; Pharmacoepidemiology

Indexed keywords

ANTIPARKINSON AGENT; LEVODOPA; SELEGILINE;

ADULT; AGED; ARTICLE; CAUSE OF DEATH; COHORT ANALYSIS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; NEUROLOGIC DISEASE; PARKINSON DISEASE; PHARMACOEPIDEMIOLOGY; TREATMENT OUTCOME;

EID: 0031964503     PISSN: 00016314     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0404.1998.tb00604.x     Document Type: Article

References (42)

1. MARTTILA RJ. Epidemiology. In: KOLLER WC, ed. Handbook of Parkinson's disease. New York: Marcel Dekker, Inc., 1992: 35-57.
2. MENNTTI-IPPOLITO F, SPILA-ALEGIANI S, VANACORE N, et al. Estimate of parkinsonism prevalence through drug prescription histories in the Province of Rome, Italy. Acta Neurol Scand 1995: 92: 49-54.
3. BONIFATI V, VANACORE N, BELLATRECCIA A, MECO G. Mortality rates for parkinsonism in Italy (1969 to 1987). Acta Neurol Scand 1993: 87: 9-13.
4. BEN-SHLOMO Y. How far are we in understanding the cause of Parkinson's disease? J Neurol Neurosurg Psychiatry 1996: 61: 4-16.
5. HOEHN MM, YAHR MD. Parkinsonism: onset, progression, and mortality. Neurology 1967: 17: 427-42.
6. SWEET RD, MCDOWELL FH. Five years' treatment of Parkinson's disease with Levodopa. Therapeutic results and survival of 100 patients. Ann Intern Med 1975: 83: 456-63.
7. BARBEAU A. Six years of high-level Levodopa therapy in severely akinetic parkinsonian patients. Arch Neurol 1976: 33: 333-8.
8. DIAMOND SG, MARKHAM CH. Present mortality in Parkinson's disease: the ratio of observed to expected deaths with a method to calculate expected deaths. J Neural Transm 1976: 38: 259-69.
9. ZUMSTEIN H, SIEGFRIED J. Mortality among Parkinson patients treated with L-dopa combined with a decarboxylase inhibitor. Eur Neurol 1976: 14: 321-7.
10. MARTTILA RJ, RINNE UK, SHRTOLA T, SONNINEN V. Mortality of patients with Parkinson's disease treated with Levodopa. J Neurol 1977: 216: 147-53.
11. JOSEPH C, CHASSAN JB, KOCH ML. Levodopa in Parkinson disease: a long-term appraisal of mortality. Ann Neurol 1978: 3: 116-18.
12. DIAMOND SG, MARKHAM CH. Mortality of Parkinson patients treated with Sinemet. Adv Neurol 1979: 24: 489-97.
13. CURTIS L, LEES AJ, STERN GM, MARMOT MG. Effect of L-dopa on course of Parkinson's disease. Lancet 1984: 2: 211-12.
14. RAJPUT AH, OFFORD KP, BEARD CM, KURLAND LT. Epidemiology of parkinsonism: incidence, classification, and mortality. Ann Neurol 1984: 16: 278-82.
15. HOEHN MMM. Parkinson's disease: progression and mortality. Adv Neurol 1986: 45: 457-61.
16. CEDARBAUM JM, MCDOWELL FH. Sixteen-year follow-up of 100 patients begun on levodopa in 1968: emerging problems. Adv Neurol 1986: 45: 469-72.
17. DIAMOND SG, MARKHAM CH, HOEHN MM, MCDOWELL, FH, MUENTER MD. Effect of age at onset on progression and mortality in Parkinson's disease. Neurology 1989: 39: 1187-90.
18. EBMEIER KP, CALDER SA, CRAWFORD JR, STEWART L, BESSON JAO, MUTCH WJ. Parkinson's disease in Aberdeen: survival after 3.5 years. Acta Neurol Scand 1990: 81: 294-9.
19. KURODA K, TATARA K, TAKATORIGE T, SHINSHO F. Effect of physical exercise on mortality in patients with Parkinson's disease. Acta Neurol Scand 1992: 86: 55-9.
20. BEN-SHLOMO Y, MARMOT MG. Survival and cause of death in a cohort of patients with parkinsonism: possible clues to aetiology? J Neurol Neurosurg Psychiatry 1995: 58: 293-9.
21. WERMUTH L, STENAGER EN, STENAGER E, BOLDSEN J. Mortality in patients with Parkinson's disease. Acta Neurol Scand 1995: 92: 55-8.
22. LEES AJ on behalf of the Parkinson's disease Research Group of the United Kingdom. Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease. BMJ 1995: 311: 1602-7.
23. BENNETT DA, BECKETT LA, MURRAY AM et al. Prevalence of parkinsonian signs and associated mortality in a community population of older people. N Engl J Med 1996: 334: 71-6.
24. LOUIS ED, MARDER K, COTE L, TANG M, MAYEUX R. Mortality from Parkinson's Disease. Arch Neurol 1997: 54: 260-4.
25. Nordic Council of Medicines guidelines for ATC classification. NLN Publication, Upssala (Sweden), 1990.
26. MARSH GM, EHLAND J, PAIK M, PREININGER ME, CAPLAN RJ. OCMAP/PC: a user oriented occupational cohort mortality analysis program for the IBM PC. Amer Stat 1986: 40: 308-9.
27. MONSON RR. Occupational Epidemiology. CRC Press, Inc., Boca Raton, Florida, 1980.
28. UITTI RJ, AHLSKOG JE, MARAGANORE DM et al. Levodopa therapy and survival in idiopathic Parkinson's disease: Olmsted County project. Neurology 1993: 43: 1918-26.
29. TREVES TA, DE PEDRO-CUESTA J. Parkinsonism mortality in the US, 1. Time and space distribution. Acta Neurol Scand 1991: 84: 389-97.
30. KOLLER WC, HUBBLE JP. Classification of parkinsonism. In: KOLLER WC, ed. Handbook of Parkinson's disease. New York: Marcel Dekker, Inc., 1992: 59-103.
31. FACTOR SA, MOLHO ES, F PODSKALNY GD, BROWN D. Parkinson's disease: drug-induced psychiatric states. Adv Neurol 1995: 65: 115-38.
32. MORANO A, JIMENEZ-JIMENEZ FJ, MOLINA JA, ANTOLIN MA. Risk-factors for Parkinson's disease: case-control study in the province of Caceres, Spain. Acta Neurol Scand 1994: 89: 164-70.
33. STRUCK LK, RODNITZKY RL, DOBSON JK. Stroke and its modification in Parkinson's disease. Stroke 1990: 21: 1395-9.
34. LEVINE RL, JONES JC, BEE N. Stroke and Parkinson's disease. Stroke 1992: 23: 839-42.
35. IZQUIERDO-ALONSO JL, JIMENEZ-JIMENEZ FJ, CABRERA-VALDIVIA F, MANSILLA-LESMES M. Airway dysfunction in patients with Parkinson's disease. Lung 1994: 172: 47-55.
36. GORELL JM, COLE JOHNSON C, RYBICKI BA. Parkinson's disease and its comorbid disorders: an analysis of Michigan mortality data, 1970 to 1990. Neurology 1994: 44: 1865-8.
37. MOLLER H, MELLEMKJAFR L, MCLAUGHLIN JK, OLSEN JH. Occurrence of different cancers in patients with Parkinson's disease. BMJ 1995: 310: 1500-1.
38. JANSSON B, JANKOVIC J. Low cancer rates among patients with Parkinson disease. Ann Neurol 1985: 17: 505-9.
39. RIGGS JE. Cigarette smoking and Parkinson's disease: the illusion of a neuroprotective effect. Clin Neuropharmacol 1992: 15: 88-99.
40. MORENS DM, GRANDINETTI A, REED D, WHITE LR, ROSS GW. Cigarette smoking and protection from Parkinson's disease: false association or etiologic clue? Neurology 1995: 45: 1041-51.
41. LARRICK JW, WRIGHT SC. Smoking and neurodegenerative diseases. Lancet 1993: 342: 1238-9.
42. MARTTILA RJ, RINNE UK. Arteriosclerosis, heredity, and some previous infections in the etiology of Parkinson's disease. A case-control study. Clin Neurol Neurosurg 1976: 79: 46-56.